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Abstract
Background: Diabetic retinopathy is a common complication of diabetes and the leading cause of irreversible vision
loss in the Western world. The reduction in color/contrast sensitivity due to the loss of neural cells in the ganglion cell
layer of the retina is an early event in the onset of diabetic retinopathy. Multipotent mesenchymal stromal cells (MSCs)
are an attractive tool for the treatment of neurodegenerative diseases, since they could differentiate into neuronal cells,
produce high levels of neurotrophic factors and reduce oxidative stress. Our aim was to determine whether the
intravitreal administration of adipose-derived MSCs was able to prevent the loss of retinal ganglion cells in
diabetic mice.
Methods: Diabetes was induced in C57BL6 mice by the administration of streptozotocin. When retinal pro-damage
mechanisms were present, animals received a single intravitreal dose of 2 × 105 adipose-derived MSCs or the vehicle.
Four and 12 weeks later we evaluated: (a) retinal ganglion cell number (immunofluorescence); (b) neurotrophic factor
levels (real-time quantitative polymerase chain reaction (RT-qPCR) and enzyme-linked immunosorbent assay (ELISA));
(c) retinal apoptotic rate (TUNEL); (d) retinal levels of reactive oxygen species and oxidative damage (ELISA); (e) electrical
response of the retina (electroretinography); (f) pro-angiogenic and anti-angiogenic factor levels (RT-qPCR and ELISA); and
(g) retinal blood vessels (angiography). Furthermore, 1, 4, 8 and 12 weeks post-MSC administration, the presence of donor
cells in the retina and their differentiation into neural and perivascular-like cells were assessed (immunofluorescence and
flow cytometry).
Results: MSC administration completely prevented retinal ganglion cell loss. Donor cells remained in the vitreous cavity
and did not differentiate into neural or perivascular-like cells. Nevertheless, they increased the intraocular levels of several
potent neurotrophic factors (nerve growth factor, basic fibroblast growth factor and glial cell line-derived neurotrophic
factor) and reduced the oxidative damage in the retina. Additionally, MSC administration has a neutral effect on
the electrical response of the retina and did not result in a pathological neovascularization.
Conclusions: Intravitreal administration of adipose-derived MSCs triggers an effective cytoprotective microenvironment
in the retina of diabetic mice. Thus, MSCs represent an interesting tool in order to prevent diabetic retinopathy.
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Background
Diabetic retinopathy (DR) is one of the most common
and frightening complications in patients with diabetes
mellitus (DM) [1] and the leading cause of irreversible
vision loss in developed countries [2]. In the Western
world, the prevalence of DR in patients with DM is
around 28 %, and strongly increases with the progression
of DM [3]. Hence, almost all patients with Type 1 DM
and 60 % of those with Type 2 DM will have some
degree of DR after 20 years of DM evolution [4, 5].
Through the years, DR has been recognized primarily
as a vascular disorder that involves pericyte loss, base-
ment membrane thickening and endothelial dysfunction
involving loss of retinal barrier integrity which leads to
hemorrhage, vascular obliteration and the resulting neo-
vascularization [6]. These events subsequently cause fi-
brovascular proliferation and blindness [6]. Nevertheless,
it has been well documented that the hyperglycemic
state adversely affects the entire neurosensory retina,
and accelerates neuronal apoptosis [7, 8]. Thus, today
DR is also considered a sensory neuropathy [9].
Although the molecular mechanisms by which DM
induces neuronal degeneration and dysfunction are still
not well understood, the role of hyperglycemia and the
generation of reactive oxygen species (ROS) due to its
exacerbating metabolism seem to be the most influen-
tial factor [10, 11]. ROS are mainly produced in the
mitochondria through the electron transport chain, and
it is well known that elevated ROS levels affect the
survival and function of retinal neurons [12]. Excessive
production of ROS results in the oxidative damage of
several biomolecules including lipids, proteins and
DNA. Retinal ganglion cells (RGCs) and glial cells are
particularly sensitive to ROS-induced damage, which
leads to the early death of these cells by apoptosis [13].
Additionally, it has been reported that increased ROS
levels reduce the retinal levels of neurotrophic factors,
including nerve growth factor (NGF), brain-derived
neurotrophic factor (BDNF) and glial cell line-derived
neurotrophic factor (GDNF), accelerating neuronal
death [10, 12].
Nowadays, available treatments for DR are applic-
able in advanced stages of the disease and are primar-
ily intended to regulate vascular changes principally
mediated by the action of vascular endothelial growth
factor (VEGF). These include laser treatment to des-
troy the hypoxic retinal cells that produce VEGF or
the intravitreal administration of anti-VEGF drugs
[14]. However, these therapies have only targeted the
vascular pathology and have achieved limited success
[15]. Therefore, the future generation of therapies
that, applied at early stages of DR, can target the
neural tissue eliciting a better visual prognosis are
highly desirable.
Recently, the use of stem cells for the management of
eye diseases has generated considerable interest [16].
Among the different type of stem cells, multipotent
mesenchymal stromal cells (MSCs), also referred to as
mesenchymal stem cells, appear as an ideal candidate
for a cell therapy for DR because: (a) they can be ob-
tained from different sources without major complica-
tions [17]; (b) they can be easily ex-vivo expanded [17];
(c) they can differentiate into neural cells or perivascular
cells [18, 19], replacing the cells that are damaged during
the course of DR; (d) they are able to secrete high levels
of potent neuroprotective factors, including NGF, BDNF
and GDNF [20, 21] that can reduce the apoptosis of
neuronal cells in the retina; (e) they efficiently scavenge
ROS, reducing the oxidative damage of the target tissues
[22, 23]; and (f ) MSCs have been used in cell therapy
strategies to treat patients with different diseases, pro-
viding favorable outcomes without significant side
effects [24, 25].
Previous work has demonstrated that the intravitreal
injection of MSCs can help to ameliorate and repair
different retinopathic injuries, mainly by the stabilization
of retinal microvasculature [26, 27].
In this study, we evaluated whether an intravitreal
administration of adipose-derived MSCs was able to
prevent the loss of RGCs in diabetic mice. For this,
severe diabetes was induced in C57/BL6 mice by the
administration of a single high dose (200 mg/kg) of
streptozotocin (STZ) [28, 29]. Diabetes progression was
evaluated according to the levels of glucose, insulin and
glycated hemoglobin in blood samples. Twelve weeks
after diabetes induction, animals were randomly as-
signed into two groups: one group received a single in-
travitreal administration of 2 × 105 adipose-derived
MSCs (DM +MSC mice) and the other group received
the vehicle (DM mice). In addition, a third group of
nondiabetic animals (Normal mice) was included as
control. Four and 12 weeks post-MSC administration,
we evaluated: (a) RGC number by immunofluorescence;
(b) the levels of neuroprotective factors by real-time
quantitative polymerase chain reaction (RT-qPCR) and
enzyme-linked immunosorbent assay (ELISA); (c) ret-
inal apoptotic rate by TUNEL; (d) retinal ROS levels
and oxidative damage by ELlSA; (e) electrical response
of the retina by electroretinography; (f ) pro-angiogenic
and anti-angiogenic factors levels by RT-qPCR and
ELISA; and (g) retinal blood vessels by angiography.
Furthermore, 1, 4, 8 and 12 weeks post-MSC adminis-
tration, the presence of donor cells in the retina and
their differentiation into neural and perivascular-like
cells were assessed by immunofluorescence and flow
cytometry.
We found that the intravitreal administration of
MSCs increases neurotrophic factor levels, reduces
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C57BL/6 and C57BL76-Tg(ACTB-EGFP)1Obs mice
(Jackson Laboratory, Bar Harbor, ME, USA) were
housed at constant temperature and humidity, with a
12:12 hour light–dark cycle and unrestricted access to
standard diet and water. When required, animals were
lightly anesthetized with sevofluorane (Abbot, Tokyo,
Japan) or deeply anesthetized with ketamine (Drag Pharma,
Santiago, Chile) plus xylazine (Centrovet, Santiago, Chile).
All animal protocols used were approved by the Ethic
Committee of Facultad de Medicina Clínica Alemana-
Universidad del Desarrollo.
Diabetes induction
Ten-week-old male C57BL/6 mice were lightly anesthetized
and received an intraperitoneal injection of 200 mg/kg STZ
(Calbiochem, La Jolla, CA, USA) immediately after
dissolving it in 0.1 M citrate buffer pH 4.5 (DM mice),
or citrate buffer only (Normal mice). It has been re-
ported that this protocol of STZ administration causes
a massive cytotoxic destruction of beta-pancreatic cells
generating a condition of severe hyperglycemia, which
accelerates the appearance of the secondary complica-
tions associated with diabetes [28, 30].
Blood glucose quantification
Blood samples were collected from the tail vein of non-
fasted alert animals, and glucose levels were determined
with the glucometer system Accu-Chek Performa from
Roche Diagnostic (Mannheim, Germany).
Plasma insulin quantification
Blood samples were collected from the tail vein of
fasted alert animals. Plasma was recovered by centrifu-
gation, and insulin concentrations were measured using
a mouse insulin ultrasensitive ELISA kit (Mercodia,
Uppsala, Sweden).
Glycated hemoglobin quantification
Blood samples were collected from the tail vein of fasted
alert animals, and HbA1c percentages were assessed using
the DCA2000 analyzer (Bayer Corporation, Pittsburgh,
PA, USA) as previously described [31].
Isolation, ex vivo expansion and characterization of MSCs
Eight- to 10-week-old female C57BL/6 or C57BL/6-
Tg(ACTB-EGFP)1Obs mice were sacrificed by cervical
dislocation. Epididymal fat was dissected, washed with
phosphate-buffered saline (PBS) and cut into small pieces.
Tissues were then digested with 1 mg/mL collagenase type
II (Gibco, Grand Island, NY, USA) in PBS and incubated
with agitation at 37 °C for 2 hours. At the end of digestion,
10 % fetal bovine serum (FBS; Gibco, Auckland, New
Zealand) was added to neutralize collagenase. The mixture
was then centrifuged at 400 g for 10 minutes to remove
floating adipocytes. Pellets were re-suspended in α-
minimum essential medium (α-MEM; Gibco) supple-
mented with 10 % FBS and 0.16 mg/mL gentamicin
(Sanderson Laboratory, Santiago, Chile), plated at a
density of 7000 cells/cm2 and cultured at 37 °C in a 5 %
CO2 atmosphere. When foci reach confluence, cells
were detached with 0.25 % trypsin, 2.65 mM EDTA
(Sigma-Aldrich, St. Louis, MO, USA), centrifuged and
subcultured at 7000 cells/cm2. After two subcultures,
cells were characterized according to their adipogenic
and osteogenic differentiation potential. For this, MSCs
were incubated with standard adipogenic or osteogenic
differentiation media for 14 and 21 days, respectively.
To evaluate the adipogenic potential, cultures were
stained with Oil Red (Sigma-Aldrich). To evaluate the
osteogenic potential, cultures were fixed with 10 % formal-
dehyde and stained with Alizarin Red (Sigma-Aldrich) as
previously described [28]. Immunophenotyping was per-
formed by flow cytometry analysis after immunostaining
with monoclonal antibodies against the putative murine
MSC markers α-SMA (FITC-conjugated; BD Bioscience,
San Jose, CA, USA), Sca-1 (PE-conjugated; eBioscience,
San Diego, CA, USA), and CD90 (PECy7-conjugated;
eBioscience), or characteristic markers of hematopoietic
cell lineages CD45 (AF780-conjugated; BD Bioscience)
and CD11b (PECy5-conjugated; eBioscience).
Intravitreal administration of MSCs
Twelve weeks after DM induction, mice were lightly anes-
thetized and 0.5 % proparacaine (Alcon, Santiago Chile)
was topically applied. A cell suspension containing 2 × 105
MSCs, passage 2, in 2 μL saline (DM+MSC mice), or
2 μL saline (DM mice) was slowly injected into the vit-
reous cavity through the pars plana using a 33-gauge
microsyringe (Hamilton, Reno, NV, USA). Eyes showing
massive vitreous hemorrhaging after the injection were
excluded from the study.
Quantification of RGCs
Animals were euthanatized by cervical dislocation and
eyes were enucleated and fixed in 4 % paraformaldehyde
(Merck, Darmstadt, Germany). Fixed eyes were orientated
to permit radial sectioning and embedded in paraffin. Eyes
were sectioned (4 μm), and sections were deparaffinized
and incubated with rat anti-mouse beta-3-tubulin anti-
body (marker of RGCs) (Santa Cruz Biotechnology,
Dallas, TX, USA). Afterwards, sections were washed and
incubated with anti-rat-Alexa555 secondary antibody
(Vector Labs, Burlingame, CA, USA) and counterstained
Ezquer et al. Stem Cell Research & Therapy  (2016) 7:42 Page 3 of 17
with 4’-6’-diamidino-2-phenylindole (DAPI; Invitrogen,
Grand Island, NY, USA). Only sections that included a full
length of retina approximately along the horizontal merid-
ian, passing through the ora serrata and the optic nerve in
both the temporal and nasal hemispheres were used. The
number of RGCs in the ganglion cell layer was quantified
by counting labeled cells from the temporal to the nasal
ora serrata in five serial sections using the Fluoview
FV10i confocal microscope (Olympus, Tokyo, Japan).
Samples were blind-analyzed by two independent ob-
servers. Data were presented as number of RGCs per
100 μm of retina length [32].
Detection of donor MSCsGFP
For in situ detection of MSCsGFP, eyes were fixed in 4 %
paraformaldehyde. One day later, they were embedded
in paraffin and radially sectioned. Four-micrometer-thick
sections were deparaffinized, incubated with rabbit anti-
GFP antibody (eBioscience) at 4 °C overnight, incubated
with goat anti-rabbit-FITC antibody (Vector Labs) at
room temperature for 1 hour, and counterstained with
DAPI. Sections were examined with the Fluoview FV10i
confocal microscope.
For the quantification of MSCsGFP, eyes were washed
twice with ice-cold PBS, chopped and digested with
1 mg/mL collagenase type II at 37 °C for 30 minutes.
Collagenase was inactivated with 10 % FBS and cell
suspensions were filtered through a 100-μm strainer and
washed twice with ice-cold PBS. To ensure MSCGFP rec-
ognition, cells in the suspension were fixed and perme-
abilized with BD Cytofix/Cytoperm kit (BD Pharmingen,
San Jose, CA, USA) and suspended in 1 mL PBS with
2 % FBS plus 1 μL undiluted anti-GFP AlexaFluor647
antibody (Molecular Probes, Grand Island, NY, USA).
After incubation at 4 °C for 12 hours, cells were washed,
filtered through a 30-μm mesh and acquired in a CyAn
ADP flow cytometer (DakoCytomation, Carpinteria, CA,
USA) as previously described [33]. Data were analyzed
with Summit v4.3 software. Criteria used to consider an
event as an MSCsGFP were forward scatter and side scat-
ter similar to ex vivo expanded MSCs and positive fluor-
escence both in FL1 (GFP) and FL8 (anti-GFP
AlexaFluor647) channels. Eyes from untreated diabetic
mice were used as autofluorescence controls. Results were
presented as number of MSCsGFP per eye.
Evaluation of MSCsGFP differentiation into neural-like or
perivascular-like cells
To determine whether donor MSCs differentiated into
neural-like cells, eye sections were co-stained with
rabbit anti-GFP antibody (eBioscience) and rat anti-
mouse beta-III-tubulin antibody (marker of RCGs)
(Santa Cruz Biotechnology) or were co-stained with
rabbit anti-GFP antibody and rat anti-mouse GFAP
antibody (marker of retinal astrocytes) (Santa Cruz
Biotechnology). Afterwards, sections were washed and
incubated with anti-rabbit-FITC and anti-rat-Alexa555
secondary antibodies (Vector Labs) and counterstained
with DAPI.
To determine whether donor MSCs differentiated into
perivascular-like cells, eyes were fixed for 2 hours in 4 %
paraformaldehyde. Afterwards, the cornea and lens were
removed and the retina was dissected and flattened onto
silanized glass slides facilitated by four equidistant radial
cuts into the peripheral retina. Wholemounts were
permeabilized with 1 % digitonin (Calbiochem) in PBS at
room temperature for 1 hour and immunohistochemi-
cally stained by overnight incubation with rabbit anti-
GFP antibody and rat anti-mouse NG2 antibody (marker
of pericytes) (Millipore, Darmstadt, Germany) at 4 °C.
Samples were also incubated with Isolectin GS-IB4 from
Griffonia simplicifolia conjugated to AlexaFluor647 (Life
Technology, Grand Island, NY, USA) to allow the de-
tection of retinal capillaries. Afterwards, samples were
washed and incubated with anti-rabbit-FITC and anti-
rat-Alexa555 secondary antibodies (Vector Labs).
In all cases, retinal tissues without exposure to the pri-
mary antibodies were used as controls for immunostain-
ing. Samples were analyzed under confocal microscopy
by taking optical sections of 1 μm. Data were analyzed
with the Olympus FV10-ASW2.1 software.
Quantification of mRNA levels of neurotrophic,
pro-angiogenic and anti-angiogenic factors
Eyes were enucleated and washed two times with ice-
cold PBS. Total RNA was purified using Absolutely
RNA Miniprep kit (Stratagene, Santa Clara, CA, USA).
One microgram of total RNA was used for reverse tran-
scription. RT-PCR reactions were performed in a final
volume of 10 μL containing 50 ng cDNA, PCR
LightCycler-DNA Master SYBERGreen reaction mix
(Roche, Indianapolis, IN, USA), 3 mM MgCl2 and
0.5 μM of the primers for the amplification of NGF,
basic fibroblast growth factor (bFGF), GDNF, BDNF,
ciliary neurotrophic factor (CNTF), VEGF-α, platelet-
derived growth factor (PDGF), angiopoietin 1 (ANG-1)
and thrombospondin-1 (TSP-1) (Additional file 1:
Table S1), using a Light-Cycler 1.5 thermocycler
(Roche). To ensure that amplicons were from mRNA
and not for genomic DNA amplifications, controls
without reverse transcription were included. Ampli-
cons were characterized according to their size evalu-
ated by agarose gel electrophoresis and to their
melting temperature determined in the LightCycler
thermocycler. Relative quantifications were performed
by the ΔΔCT method. The mRNA level of each target
gene was standardized against the mRNA level of
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GAPDH, for the same sample. Results were presented
as fold-change versus normal mice.
Quantification of protein levels of neurotrophic and
anti-angiogenic factors
Eyes were enucleated and washed two times with ice-
cold PBS. Samples were mechanically lysed in lysis buf-
fer (RayBiotech, Norcross, GA, USA) containing a prote-
ase inhibitor cocktail (Thermo, Waltham, MA, USA)
and centrifuged at 12,000 g for 10 minutes. The levels of
NGF, bFGF, GDNF and TSP-1 were measured in the
supernatant of the lysates using the Mouse beta-NGF
ELISA kit (RayBiotech), Mouse FGF basic Quantikine
ELISA kit (R&D Systems, Minneapolis MN, USA), Mouse
GDNF ELISA kit (MyBioSource, San Diego, CA, USA)
and Mouse thrombospondin 1 ELISA kit (MyBioSource),
respectively. Data were normalized per mg of protein
present in each sample.
Quantification of apoptotic cells
The presence of apoptotic cells in the retina was evalu-
ated by the TUNEL technique in 4-μm thick sections of
the eye, using the In Situ Cell Death Detection Kit
(Roche) following the manufacturer’s instructions. In
each experiment, adjacent sections incubated without
TdT served as negative control. Nuclei were counter-
stained with DAPI and samples were observed by confocal
microscopy. Each section was scanned systematically from
the temporal to the nasal ora serrata looking for fluores-
cent cells indicative of apoptosis. The number of TUNEL-
positive cells per section was determined using the
Olympus FV10-ASW2.1 software, and the apoptosis
rate was expressed as fold-change versus normal mice.
Quantification of ROS
Retinas were carefully dissected and mechanically lysed
in lysis buffer (RayBiotech) containing a protease inhibi-
tor cocktail. For quantification of ROS level, equal
volumes of retinal lysates were incubated with 10 μmol/
L 2,7-dichloro-dihydro-fluorescein diacetate (H2DCFDA;
Invitrogen) for 1 hour at 37 °C. Fluorescence was mea-
sured in a fluorimeter (Turner, Sunnyvale, CA, USA)
with excitation of 485 nm and emission of 520 nm as
previously reported [34]. Data were normalized per mg
of protein present in each sample and expressed as fold-
change versus normal mice.
Quantification of oxidative damage
Lipid peroxidation was determined by a method that
measures the amount of thiobarbituric acid reactivity by
the amount of malondialdehyde (MDA) formed during
acid hydrolysis of the lipid peroxide compounds using
the Lipid Peroxidation MDA Assay kit (Cayman, Ann
Arbor, MI, USA). Retinas were mechanically lysed in lysis
buffer (RayBiotech) containing a protease inhibitor cock-
tail and the antioxidant butyl hydroxytoluene (BHT). Lipid
peroxidation was quantified sprectophotometrically at
540 nm (Thermo spectronic). MDA level was normalized
per mg of protein present in each sample.
Protein nytrosilation was quantified in retinal lysates
containing a protease inhibitor cocktail, measuring ni-
trotyroxine level with the 3-Nitrotyrosine ELISA kit
(Abcam, Cambridge, UK) following the manufacturer’s
instructions. The nitrotyroxine level was normalized
per mg of protein present in each sample.
DNA oxidation was measured in genomic DNA iso-
lated from retinal samples by DNAzol (Invitrogen).
DNA was digested by incubation with DNAsa RQ1
(Promega, Madison, WI, USA) and 8-OHdG levels
were quantified using the Oxidative DNA damage
ELISA kit, following the manufacturer’s instructions.
8-OHdG levels were normalized per μg of DNA
present in each sample.
For all oxidative markers, data were expressed as fold-
change versus normal mice.
Evaluation of retinal electrical response
Evaluation of retinal function was carried out by electro-
retinography (ERG) using the Handheld Multi-species
ElectroRetinoGraph Instrument (Ocuscience, Kansas
City, MO, USA). In brief, the animals were prepared
under red light illumination, anesthesia was provided by
the inhaled administration of sevoflurane and pupils
were dilated by using tropicamide acetate (Alcon). Body
temperature was maintained at 37 °C with a heating
plate. All animals recovered from anesthesia after the
procedure.
Previous to the measurements, mice were main-
tained for a period of dark adaptation of 16 hours. The
electrical responses were registered by using a corneal
electrode with methylcellulose as a coupling agent.
Reference and ground electrodes were placed in the
ear and in the tail, respectively. Stimulation and par-
ameter recording were carrying out as defined by the
international Society for Clinical Electrophysiology of
Vision (ISCEV). In brief, flash stimuli were as follows:
0.01 and 3.0 cd · s · m–2 in scotopic and photopic con-
ditions. The a-wave amplitude was measured from the
baseline to the trough of the a-wave and the b-wave
amplitude was measured from the trough of the a-
wave to the peak of the b-wave as previously reported
[35]. Oscillatory potentials (OPs) were isolated by
treating measurements with a digital bandpass filter
between 60 and 200 Hz, after dark adaptation using
3.0 cd · s · m–2 flash stimuli. The peak amplitudes of the
first six waves were recorded from baseline, as previ-
ously described [36].
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Quantification of retinal vasculature and detection of
vascular leakage
Animals were lightly anesthetized and injected in the tail
vein with 0.2 mL saline containing 10 mg of 2 × 106 mo-
lecular weight fluorescein-dextran (Sigma-Aldrich). Five
minutes later, animals were euthanatized by cervical dis-
location and eyes were enucleated and fixed in 4 % para-
formaldehyde for 2 hours. Afterwards, the cornea and
lens were removed, and the retina was dissected and flat-
tened onto glass slides facilitated by four equidistant ra-
dial cuts into the peripheral retina. The flat-mounted
retinas were photographed by confocal microscopy and
at least 15 images per animal were analyzed. The fluor-
escent area, representative of the retinal vascular area, of
each image was quantified using the Image J 1.34 soft-
ware (NIH, Bethesda, USA). Data were presented as ret-
inal vascular area/total retinal area. Retinal vascular
leakage was determined by the presence of areas of ex-
travasated FITC-dextran.
Statistical analysis
Data were presented as mean ± standard error of the
mean (SEM). Multiple group comparisons were per-
formed by analysis of variance (ANOVA) followed by
Bonferroni post-hoc test, while comparisons between
two experimental group were performed by Student’s t
test. p < 0.05 were considered statistically significant.
Results
Diabetes induction and retinopathy condition
To induce DM, C57BL6 mice were treated with a single
dose of 200 mg/kg STZ, since this protocol causes a
rapid and massive destruction of pancreatic beta cells
[28]. Diabetic mice were maintained without insulin sup-
plementation to allow for the progression of severe dia-
betes and the appearance of its complications, including
DR. Ten days after STZ administration, blood glucose
levels reached their highest concentration, which was
three times higher than in normal individuals (Fig. 1a).
Twelve weeks after DM induction, elevated blood glu-
cose level was also correlated with a severe reduction in
plasma insulin level and a marked increase in glycated
hemoglobin level (Fig. 1b and c). At this time, DM mice
maintained the same number of RGCs compared to age
matched normal mice (Fig. 1d and e); however, retinal
electrical response was altered. This could be evidenced
by a significant reduction in the amplitudes of the a-
wave and b-wave of the ERG of DM mice in comparison
to normal mice under stimuli of 0.01 cd · s · m–2 and
3.0 cd · s · m–2 (Fig. 1f, g and h).
Adipose-derived MSCs were isolated, expanded and
characterized according to their adipogenic and osteo-
genic potential (Fig. 2a–c), and by the presence of the
putative murine MSC markers α-SMA, SCA-1 and
CD90 and by the non-expression of markers characteris-
tics of hematopoietic cell lineages—CD45 and CD11b
(Fig. 2d). Twelve weeks after diabetes induction, DM
mice were randomly assigned into two groups: one group
that received an intravitreal administration of 2 × 105
MSCs (DM+MSC mice) and another group that received
an intravitreal administration of the vehicle (DM mice).
Additionally, we also maintained a group of normal non-
diabetic mice (Normal mice) as a control.
MSC administration prevents RGCs loss
Since one of the earliest events in the onset of DR is the
death of RGCs [13], we tested whether MSC administra-
tion was able to prevent the loss of these cells in the ret-
ina. As expected, 16 weeks after DM induction (4 weeks
after vehicle administration) DM mice presented a sig-
nificant reduction (~20 %) in the number of RGCs in
the retina. However, MSC administration completely pre-
vented this reduction (Fig. 3a and c). The preventive effect
was maintained until at least 24 weeks after diabetes in-
duction (12 weeks after MSC administration) when DM+
MSC mice presented an equivalent number of RGCs as
compared to cells in the normal mice (Fig. 3b and d).
Donor MSCs remains in the eye but do not differentiate into
neural-like or perivascular-like cells
One possibility to explain the therapeutic effect observed
is that the administered MSCs could differentiate into
RGCs, replacing the damaged cells, or into another
neural or perivascular cell type that could act as a sup-
port cell to prevent RGC death. To assess this possibil-
ity, first we evaluated whether administered MSCs could
remain in the eye and integrate into the retina of DM
mice. Using MSCs isolated from transgenic mice that
constitutively express GFP, we observed by flow cytome-
try and immunohistofluorescence that the number of
donor cells in the eyes were decreasing over time,
but they were still detectable 12 weeks after their
administration (Fig. 4). Most donor cells remained in
the vitreous cavity and did not integrate into the ret-
ina (Fig. 4c). To evaluate whether MSCs could differ-
entiate into neural or perivascular cells we tried to
colocalize GFP with a marker of RGCs (β3-tubulin)
(Fig. 5a), with a marker of retinal astrocytes (GFAP)
(Fig. 5b) or with a marker of retinal pericytes (NG2)
(Fig. 5c). In most cases, GFP -positive cells did not
express any of these markers at any of the analyzed
times. However, we also detected a small number of
MSCsGFP that also expressed the marker of RGC
(Additional file 2: Figure S1A), the marker of astro-
cyte (Additional file 2: Figure S1B) or the marker of
pericyte (Additional file 2: Figure S1C).
Ezquer et al. Stem Cell Research & Therapy  (2016) 7:42 Page 6 of 17
The intravitreal administration of MSCs increases the
intraocular levels of neurotrophic factors
MSCs are known to produce, both in vitro and in vivo, a
broad range of trophic factors that have been associated
with tissue regeneration and neuronal survival [20]. To
evaluate whether the therapeutic effects observed after
MSC administration could be related to the generation
of a pro-regenerative microenvironment, the intraocular
levels of several neurotrophic factors were measured.
Four weeks after MSC administration, we observed a
significant increase in the mRNA levels of NGF, bFGF
and GDNF in the eyes of DM +MSC mice compared to
age-matched DM mice and normal mice (Fig. 6a). The
mRNA levels of NGF and bFGF remained elevated in the
Fig. 1 Characterization of diabetes mellitus (DM) stage and DR development prior to MSC administration. C57BL/6 adult male mice were injected
either with 0.1 M citrate buffer (Normal mice) or 200 mg/kg STZ in 0.1 M citrate buffer (DM mice). a Blood glucose level was determined weekly
in venous blood samples obtained from alert non-fasted animals. b Insulinemia and c glycated hemoglobin levels were determined 12 weeks
after SZT administration. Retinal histology was analyzed 12 weeks after SZT administration in serial 4-μm eye sections, immunolabeled with
β3-tubulin antibody (marker of retinal ganglion cells (RGCs)). d Samples were observed under confocal microscopy focusing on the ganglion
cell layer of the retina (arrows). e RGCs in the ganglion cell layer of the retina were quantified. f Representative ERG showing a characteristic
decreases in a-wave and b-wave in DM mice in comparison to normal mice using a stimulus of 0.01 cd · s · m–2. Black line, normal mice; blue
line, DM mice. The amplitudes of a-waves and b-waves recorded under scotopic conditions using stimuli of g 0.01 cd · s · m–2 or h 3.0 cd · s · m–2 were
quantified. Qualitative data are representative of eight eyes per group. Quantitative data correspond to mean ± SEM of eight eyes per group
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Fig. 2 Characterization of adipose-derived MSCs isolated from adult C57BL/6 mice. a Isolated cells were cultured in α-MEM containing 10 %
selected FBS into plastic dishes and differentiated into b adipogenic and c osteogenic lineages. Cells were also immunophenotyped according to
the expression of the putative murine MSC markers alpha-SMA, SCA-1 and CD90 and the non-expression of the markers characteristic of hematopoietic
cell lineages—CD45 and CD11b. d Open histograms represent cells stained with isotype controls; filled histograms represent cells labeled with specific
antibodies. Data shown are representative of cells isolated from four different normal animals
Fig. 3 Mesenchymal stromal cell (MSC) administration prevents retinal ganglion cell (RGC) loss. Twelve weeks after STZ administration, diabetic
mice received an intravitreal injection of 2 μL saline (DM) or 2 × 105 MSCs resuspended in 2 μL saline (DM +MSC). Retinal histology was analyzed
in serial 4-μm eye sections, immunolabeled with β3-tubulin antibody (marker of RGCs). Samples were observed under confocal microscopy focusing
on the ganglion cell layer of the retina (arrows), a 4 weeks and b 12 weeks after MSC administration. RGCs in the ganglion cell layer of the retina were
quantified at both experimental times (c and d). Qualitative data are representative of eight eyes per group and per analyzed time. Quantitative data
correspond to mean ± SEM of eight eyes per group and per analyzed time
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Fig. 4 Donor mesenchymal stromal cells (MSCs) remain in the eye at least until 12 weeks after their administration. Twelve weeks after STZ
administration, diabetic mice received an intravitreal dose of 2 × 105 MSCsGFP in 2 μL saline. On days 1, 4, 8 and 12 weeks later, the presence of
donor cells was assessed in the eye by flow cytometry. a Events in gate R1 represent GFP+ cells. b Data were quantified, and the dotted line represents
the detection limit. c Presence of donor cells in the eye was also corroborated by immunofluorescence. Qualitative data are representative of eight eyes
per analyzed time. Quantitative data correspond to mean ± SEM of eight eyes per analyzed time. DM Diabetes mellitus, GFP green fluorescent protein
Fig. 5 Most donor mesenchymal stromal cells (MSCs) do not differentiate into neural- or perivascular-like cells. On days 1, 4, 8 and 12 weeks after
MSC administration, immunofluorescences were performed in eye sections to evaluate differentiation of MSCs into RGCs by a colocalization of
green fluorescent protein (GFP) with the RGC marker β3-tubulin or b differentiation into retinal astrocytes by colocalization of GFP with the astrocyte marker
GFAP. c To evaluate differentiation of MSCs into perivascular cells, immunofluorescences were performed to colocalize GFP with the pericyte marker NG2
in whole mount retinal preparations. Lectin was also added to detect blood vessels. Qualitative data are representative of six eyes per analyzed time
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eye of DM+MSC mice 12 weeks post-MSC administration
(Fig. 6a). These neurotrophic factors were also elevated at
protein levels at both experimental times (Fig. 6b).
One of the main mechanisms associated with the
neuroprotective effect of neurotrophic factors is the in-
hibition of apoptosis. To evaluate whether the micro-
environment generated by the secretion of trophic factors
could reduce the apoptosis of RGCs, the apoptotic rate
was determined by the TUNEL assay. Examination of
retinas of diabetic mice showed a significant increase in
TUNEL-positive cells both in DM and DM+MSC mice 4
and 12 weeks post-administration of vehicle or MSCs
compared to age-matched normal mice (Additional file 3:
Figure S2A–D). However, in all cases, apoptotic cells were
present in the outer nuclear layer of the retina. At the ex-
perimental times evaluated, we could not find any TUNEL-
positive cell in the ganglion cell layer of the retina.
The intravitreal administration of MSCs reduces the retinal
oxidative damage
Oxidative and nitrative modifications of retinal macro-
molecules occur promptly in the course of DR and are
associated with the early death of retinal neurons [37, 38].
It has been postulated that MSCs could efficiently scav-
enge reactive species [22]. To evaluate the effect of MSC
administration on the oxidative damage of the retina, we
measured total ROS level and different markers of oxida-
tive damage 4 and 12 weeks after MSC administration. As
expected, diabetes induced a significant increase in the
total amount of oxidative species in the retina at both
experimental times compared with the oxidative species
in age-matched normal mice (Fig. 7a). The elevated ROS
levels correlated with a significant increase in the lipid
peroxidation level in the retina (Fig. 7b), but were not
enough to induce detectable oxidative damage at the pro-
tein and DNA levels (Fig. 7c and d). MSC administration
induced a small non-significant reduction in ROS levels in
the retina (Fig. 7a), but a strong reduction in lipid peroxi-
dation levels at both experiential times, reaching values
similar to those observed in normal mice (Fig. 7b).
The intravitreal administration of MSCs has a neutral effect
in the electrical response of the retina in DM mice
It is well known that prior to the development of any
histologically detectable retinal alteration, diabetic retinas
display a significant decrease in neuronal function that
could be evidenced by ERG [39]. Thus, we evaluated
whether MSC administration could improve the electrical
response in the retina of DM mice. For this we performed
dark-adapted ERG, 4 and 12 weeks after MSC admin-
istration and, using stimuli of 0.01 cd · s · m–2 and
3.0 cd · s · m–2, we observed that no matter whether
diabetic mice were treated with MSCs or only the
vehicle, they had a significant reduction in the a-wave and
b-wave amplitudes compared to age-matched normal
mice (Fig. 8a–e). We also measured Ops, since it has been
Fig. 6 The intravitreal administration of mesenchymal stromal cells (MSCs) increases the intraocular levels of neurotrophic factors. Four and 12 weeks
after the administration of MSCs or vehicle, the intraocular levels of several neurotrophic factors were measured by a RT-qPCR and b ELISA. Quantitative
data correspond to mean ± SEM of eight eyes per group and per analyzed time. BDNF Brain-derived neurotrophic factor, bFGF basic fibroblast growth
factor, CNTF ciliary neurotrophic factor, DM diabetes mellitus, GDNF glial cell line-derived neurotrophic factor, NGF nerve growth factor
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previously reported that OPs are altered in diabetic
individuals [40], and OPs are likely due to inner retinal
neurotransmission, which represents the synaptic activity
between amacrine neurons and RGCs [41]. There were no
significant differences in the amplitudes of the OPs be-
tween the experimental groups at both experimental times
analyzed (Fig. 8f).
The intravitreal administration of MSCs does not induce a
provasculogenic microenvironment in the retina
While the growth of new blood vessels is beneficial in
some ischemic conditions like ischemic heart disease
[42], neovascularization in most ocular diseases, including
DR, is devastating to visual function [6]. It is well known
that MSCs are able to secrete, in addition to neurotrophic
Fig. 7 The intravitreal administration of mesenchymal stromal cells (MSCs) reduces the retinal oxidative damage. Four and 12 weeks after the
administration of MSCs or vehicle the retinas were dissected and the levels of a reactive oxygen species (ROS), b lipid peroxidation, c protein
nitrosylation and d DNA oxidation were measured. Quantitative data correspond to mean ± SEM of eight eyes per group and per analyzed time.
DM Diabetes mellitus, MDA malondialdehyde
Fig. 8 The intravitreal administration of mesenchymal stromal cells (MSCs) has neutral effect in the electrical response of the retina in diabetes
mellitus (DM) mice. Four and 12 weeks after the administration of MSCs or vehicle, the electrical responses of the retina were measured by
ERG. a Representative ERG showed decreases in a-wave and b-wave in DM mice and in DM +MSC mice in comparison to normal mice using
a stimulus of 0.01 cd · s · m–2; black line, normal mice; blue line, DM mice; purple line, DM + MSC mice. The a-waves were quantified under
scotopic conditions using stimuli of b 0.01 cd · s · m–2 or c 3.0 cd · s · m–2. The b-waves were quantified under scotopic conditions using stimuli
of d 0.01 cd · s · m–2 or e 3.0 cd · s · m–2. f The peak amplitudes of the first six waves of the oscillatory potentials were quantified. Qualitative
data are representative of eight eyes per group and per analyzed time. Quantitative data correspond to mean ± SEM of eigth eyes per group
and per analyzed time
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factors, strong angiogenic factors [43]. This could be a
major limitation since MSC administration might worsen
DR.
To evaluate if MSC administration induce a provascu-
logenic microenvironment, the intraocular levels of pro-
angiogenic and anti-angiogenic factors were measured.
Four and 12 weeks after MSC administration, we did
not observe differences in the mRNA levels of the pro-
angiogenic factors VEGF-α, PDGF and ANG-1 in the
eyes of DM +MSC mice compared to untreated DM
mice (Fig. 9a). However, the mRNA level of TSP-1, a po-
tent anti-angiogenic factor, was significantly increased in
the eyes of DM +MSC mice compared to untreated DM
mice and normal mice at both experimental times
(Fig. 9a). The increase in TSP-1 level was also corrobo-
rated at protein level by ELISA (Fig. 9b). Additionally,
retinal blood vessel density was evaluated in retinal flat-
mounts after perfusion with high molecular weight
FITC-dextran. At both experimental times, retinas of
normal, DM and DM +MSC mice exhibited both super-
ficial and deep vascular layers that extended from the
optic nerve to the peripheral areas. The vessels formed a
fine radial branching pattern in the superficial retinal
layer and a polygonal reticular pattern in the deep retinal
Fig. 9 The intravitreal administration of mesenchymal stromal cells (MSCs) does not induce a provasculogenic microenvironment in the retina.
Four and 12 weeks after the administration of MSCs or vehicle, the intraocular levels of pro-angiogenic and anti-angiogenic factors were measured by
a RT-qPCR and b ELISA. Retinal blood vessels were visualized at both experimental times by the administration of FITC-dextran in the tail vein. c Retinas
were dissected, flat mounted and observed by confocal microscopy. d Retinal vasculature was quantified and expressed as vascular area/total retinal
area. Quantitative data correspond to mean ± SEM of eight eyes per group and per analyzed time. Qualitative data are representative of eight eyes per
group and per analyzed time. ANG1 Angiopoietin 1, DM diabetes mellitus, PDGF platelet-derived growth factor, TSP1 thrombospondin 1, VEGF vascular
endothelial growth factor
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layer (Fig. 9c). There were no differences in the amount
of blood vessels in the different experimental conditions
(Fig. 9d).
An increase in vascular permeability is an early event
in the onset of DR [44]. In our model, diabetes induced
the appearance of areas of vascular leakage compared to
normal mice. However, there was no difference in this
parameter when comparing diabetic mice treated with
vehicle or with MSCs, since in both cases we could de-
tect the occasional presence of areas of vascular leakage
(Additional file 4: Figure S3).
Discussion
Diabetic retinopathy is a major cause of visual impair-
ment and the leading cause of blindness in the Western
world [2]. Stem cell-based therapy represents a newly
emerging therapeutic approach to treat eye diseases. In
this sense, due to the matching of the pathological
events that occur at the initial stages of DR, and the
cellular and molecular mechanisms associated with the
reported MSC therapeutic effects, this approach repre-
sents a promising tool for the treatment of DR [44].
One of the first demonstrations that MSCs could play
a therapeutic role in DR came from a study in which the
intravenous administration of adipose-derived MSCs in
an animal model of DM improved the integrity of the
blood–retinal barrier [19]. However, in this study it was
not clear whether the observed therapeutic effect was
secondary to the reduced hyperglycemia, or due to a
direct effect of MSCs in the damaged retina. Recently,
more direct evidence of the role of MSCs in DR came
from studies in which adipose-derived MSCs were intra-
vitreally injected into the Akimba DR model or into
diabetic rats treated with STZ [18, 26]. In these studies,
the authors showed that MSC administration reduces
blood–retinal barrier breakdown and MSCs differentiate
into pericytes and integrate into the retinal vasculature
[18, 26]. However, it has become more clear that DR af-
fects not only retinal vasculature, but also retinal neuronal
and glial cells, and that visual deficits in the early stage of
DR are correlated with retinal neurosensory dysfunction
that is mainly related to the early loss of RGCs [8, 45].
Thus, in this work we wanted to evaluate whether the in-
travitreal administration of MSCs was able to prevent the
loss of RGCs. For this, we used an animal model of DM
induced by the administration of a single high dose of
STZ. This animal model is widely used to study the main
complications associated with DM since animals develop
sustained hyperglycemia and reduced insulinemia due to
the massive destruction of pancreatic beta cells, allowing
the appearance of the long-term complications associated
with DM, including DR [28, 29].
In this animal model, as previously reported [10], dia-
betes induces a significant reduction in the number of
RGCs. This 20 % reduction in the number of RGCs is in
agreement with data reported for other animal models
of DR [32, 46]. However, MSC administration com-
pletely prevents RGC loss, and this effect was main-
tained at least 12 weeks after the administration.
Both direct differentiation of MSCs into RGCs or in-
direct support to the neural retina by the secretion of
neuroprotective factors or by the reduction of oxidative
damage could be related to this therapeutic effect. Here
we analyzed the migration of MSCs into the retina and
the differentiation potential of these cells into RGCs, but
also into astrocytes and pericytes since it has been reported
the early damage to these cells could affect neuronal sur-
vival and the normal interactions with other retinal cells
[47, 48]. We observed that most of the administered cells
remained in the vitreous cavity, and they did not express
neural or perivascular markers. We could detect only an
extremely low number of MSCs that had adopted a puta-
tive phenotype of RGCs, astrocytes or pericytes, suggesting
that the direct differentiation of MSCs into neural- or
perivascular-like cells is not the main mechanism of the
therapeutic effect. These results are in agreement with data
of Johnson et al., who reported extremely poor retinal inte-
gration of MSCs after its intravitreal administration in an
animal model of glaucoma [49]. In this sense, several au-
thors have postulated that the pre-treatment of the retina
with different drugs is needed to allow the effective in-
corporation of the transplanted cells [49, 50].
MSCs are known to produce and secrete, both in vitro
and in vivo, a broad range of trophic factors, including
some potent neurotrophic factors that could potentially
prevent retinal neuronal cells from dying [51]. Here we
saw that MSC administration increases the intraocular
levels of NGF, GDNF and bFGF 4 and 12 weeks after in-
jection. These neurotrophic factors have previously been
involved in the inhibition of apoptosis of RGCs in differ-
ent animal models [52, 53]. Therefore, MSCs remaining
in the vitreous cavity could continuously deliver thera-
peutic molecules locally for a prolonged period of time.
Alternatively, these neuroprotective factors could be se-
creted by the host retinal tissue in response to MSC
injection.
Similar results were observed in an animal model of ex-
perimental glaucoma induced by the laser photocoagulation
of the trabecular meshwork [21]. In this animal model, the
intravitreal administration of MSCs provides trophic sup-
port to the damaged tissue, and increased RGC survival
[21]. Additionally, Yu et al. reported that intravitreal MSC
transplantation was neuroprotective after episcleral vein
ligature, which can cause moderate ocular hypertension
and RGC loss [54], and the same neuroprotective factors
were also elevated in the vitreous cavity after the intravitreal
administration of human placental stem cells in an animal
model of DR [55].
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In our model, MSC administration did not reduce the
global apoptotic rate in the retina. However, we could
not find RGCs undergoing apoptosis at any experimental
time analyzed. This could be related to the slow onset
and progression of DR, in which the number of cells
dying at any given time is very small.
A widespread oxidative damage occurs in the retina of
DR patients. Thus, in addition to providing neurotrophic
support, MSCs may also give neuroprotection in the
retina by modulating the levels of ROS. Previously we
have demonstrated that MSCs have a high resistance to
ROS due to the robust expression of SOD1, SOD2, CAT
and GPX1 enzymes and high levels of glutathione [22].
Furthermore, MSCs constitutively express the enzymes
required for the repair of oxidized structures [56].
Therefore, MSCs possess the main enzymatic machinery
to detoxify ROS and to correct the oxidative damage.
Here we showed that MSC administration induced a
small reduction in the ROS level in the retina but a
strong reduction in lipid peroxidation levels, one of the
main markers of oxidative damage in the retina [57].
Consistent with these observations, the treatment of
DM animals with antioxidants or with inhibitors of some
of the metabolic pathways that generate ROS reduces
oxidative damage of retinal structures and attenuates
retinal cell loss [58–61]. Unfortunately, these drugs have
low oral bioavailability or are not able to cross the
blood–retinal barrier. Therefore large doses must be
administrated to maintain therapeutic concentrations in-
side the retina, limiting their clinical use.
ERG is one of the most accepted techniques to evaluate
retinal electrical response in diabetic individuals. In our
animal model we observed a significant reduction in the
amplitude of the scotopic a-wave and b-wave 3 months
after diabetes induction that continued its altered state 4
and 6 months after STZ administration, but we could not
detect changes in the amplitude of the OPs. MSC admin-
istration has a neutral effect on the electrical response of
the retina. In our study we injected MSCs into the vitre-
ous cavity, since it is the nearest location to RGCs, and in
human patients intravitreal injection is technically feasible
and safe [62]. However, it has been previously reported
that cells injected into the vitreous cavity tend to cover
the back of the lens and block the passage of light into the
eye [21], altering the ERG analysis. Furthermore, we also
observed that administered MSCs adopt this location,
mainly between 7 and 30 days after its administration
(data not shown). Therefore, another administration
route, such as transplantation into the subretinal space,
should be evaluated in order to avoid this effect.
Additionally, it has been previously shown that axon
degeneration of the RGCs can occur with relative sparing
of RGC bodies [63]; therefore, the soma protection
achieved by the MSC administration in this context could
not provide a functional benefit. Further investigation will
be required to understand this effect.
One of the main concerns regarding MSC therapy for
DR is the secretion of pro-angiogenic growth factors,
mainly VEGF and PDGF, that might worsen the course
of DR. VEGF is a potent growth factor that enhances
vascular permeability, stimulates endothelial cell prolif-
eration and migration, and promotes angiogenesis in the
retina [61]. Similarly, PDGF is a pro-angiogenic growth
factor that may also promote aberrant neovasculariza-
tion in DR [64]. Furthermore, PDGF may stimulate the
formation and traction of epiretinal membranes in pa-
tients with DR [65]. However, it has been reported that,
depending on the microenvironment, MSCs could pro-
duce trophic factors that may modulate between a pro-
angiogenic and anti-angiogenic environment. Here we
showed that MSC administration did not increase the
intraocular levels of VEGF and PDGF, and did not
promote the massive formation of blood vessels or the
increase in vascular permeability. Moreover, MSC ad-
ministration increased the intraocular level of TSP-1, a
potent anti-angiogenic factor. In accordance with our
results, it has previously been shown that the local
administration of MSCs in an animal model of corneal
chemical injury, characterized by an accelerated neovas-
cularization process, produced a rapid regression of the
new blood vessels [66]. This anti-angiogenic effect was
attributed to the secretion of TSP-1 by the administered
MSCs, while the ocular levels of the pro-angiogenic fac-
tor VEGF were unchanged between the untreated and
the MSC-treated group [66].
More studies are required in order to determine the
best source and dose of MSCs and the optimal time for
their administration. Nevertheless, the ability of MSCs
to secrete neurotrophic factors and to reduce oxidative
damage of the retina, preventing RGC loss, opens the
possibility of using these cells to stop the progressive de-
terioration of the neural retina in diabetic individuals.
Conclusion
Intravitreal administration of adipose-derived MSCs trig-
gers an effective cytoprotective microenvironment in the
retina of diabetic mice. Furthermore, MSC administration
does not result in the pathological neovascularization of
the retina. Thus, MSCs represent an interesting tool in
order to prevent DR.
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Additional file 1: Table S1. Primer and amplicon characteristics.
(PNG 42 kb)
Additional file 2: Figure S1. Donor MSCs differentiate into neural- or
perivascular-like cells at very low frequency. One, 4, 8 and 12 weeks after
MSC administration immunofluorescences were performed in eye sections
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to evaluate differentiation of MSCs into RGCs by colocalization of GFP with
the ganglion cell marker β3-tubulin (A) or differentiation into astrocytes
by colocalization of GFP with the astrocyte marker GFAP (B). To evaluate
differentiation of MSCs into perivascular cells, immunofluorescences were
performed to colocalize GFP with the pericyte marker NG2 in whole mount
retinal preparations. Lectin was also added to detect blood vessels. Arrows
indicate cells co-expressing both markers. Qualitative data are representative
of six eyes per analyzed time. (PNG 2819 kb)
Additional file 3: Figure S2. MSC administration does not modify the
apoptotic rate in the retina of DM mice. Apoptosis in the retina was
analyzed by the TUNEL technique in serial 4-μm eye sections 4 weeks
after MSC administration (A) and 12 weeks after MSC administration (B).
Nuclei were counterstained with DAPI. Arrows indicate TUNEL-positive cells.
The number of apoptotic nuclei was quantified at both experimental times
and expressed as fold-change versus normal mice (C and D). Qualitative
data are representative of eight eyes per analyzed time. Quantitative data
correspond to mean ± SEM of eight eyes per group and per analyzed time.
(PNG 3862 kb)
Additional file 4: Figure S3. MSC administration does not modify the
presence of vascular leakage areas in the retina of DM mice. FITC-dextran
was administered in the tail vein 4 and 12 weeks after the administration
of MSCs or vehicle. Retinas were dissected, flat mounted and observed
by confocal microscopy. Retinal vascular leakage was determined by the
presence of areas of extravasated FITC-dextran marked by arrows. Qualitative
data are representative of eight eyes per group and per analyzed time.
(PNG 2029 kb)
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